EX-99.3 4 d429669dex993.htm PRESENTATION SLIDES Presentation Slides
1
1
Third Quarter 2012
Conference Call
Third Quarter 2012
Conference Call
NASDAQ:
QCOR
Exhibit 99.3


2
Today’s webcast, accompanying slide presentation
and archived replay is available online at
Telephone replay is available by dialing:
U.S.: (855) 859-2056.
International: (404) 537-3406.
Passcode: 39696380
By webcast: At Questcor's investor relations website:
Today’s webcast, accompanying slide presentation
and archived replay is available online at
Telephone replay is available by dialing:
U.S.: (855) 859-2056.
International: (404) 537-3406.
Passcode: 39696380
By webcast: At Questcor's investor relations website:
Conference Call Logistics
2
http://ir.questcor.com/
http://ir.questcor.com/events.cfm


3
Safe Harbor Statement
Note: Except for the historical information contained herein, this press release contains forward-looking statements that
have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or
our future financial performance. In some cases, you can identify forward-looking statements by terminology such as
"believes," "continue," "could," "estimates," "expects," "growth," "may," "plans," "potential," “remain,” "should,"
"substantial" or "will" or the negative of such terms and other comparable terminology. These statements are only
predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include,
but are not limited to, the following: Our reliance on Acthar for substantially all of our net sales and profits; Reductions in
vials used per prescription resulting from changes in treatment regimens by physicians or patient compliance with physician
recommendations; The complex nature of our manufacturing process and the potential for supply disruptions or other
business disruptions ;The lack of patent protection for Acthar; and the possible FDA approval and market introduction of
competitive products; Our ability to continue to generate revenue from sales of Acthar to treat on-label indications
associated with NS, and our ability to develop other therapeutic uses for Acthar; Research and development risks, including
risks associated with Questcor's work in the area of NS and potential work in the area of Rheumatology, and our reliance on
third-parties to conduct research and development and the ability of research and development to generate successful
results; Our ability to comply with federal and state regulations, including regulations relating to pharmaceutical sales and
marketing practices; The results of any pending or future litigation, investigations or claims, including with respect to the
investigation by the United States Attorney’s Office for the Eastern District of Pennsylvania regarding the Company’s
promotional practices; Regulatory changes or other policy actions by governmental authorities and other third parties in
connection with U.S. health care reform or efforts to reduce federal and state government deficits; Our ability to receive high
reimbursement levels from third party payers; An increase in the proportion of our Acthar unit sales comprised of Medicaid-
eligible patients and government entities; Our ability to estimate reserves required for Acthar used by government entities
and Medicaid-eligible patients and the impact that unforeseen invoicing of historical Medicaid prescriptions may have upon
our results; Our ability to effectively manage our growth, including the expansion of our sales forces, and our reliance on key
personnel; The impact to our business caused by economic conditions; Our ability to protect our proprietary rights; The risk
of product liability lawsuits; Unforeseen business interruptions and security breaches; Volatility in Questcor's monthly and
quarterly Acthar shipments, estimated channel inventory, and end-user demand, as well as volatility in our stock price; and
Other risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2011 as filed with the
Securities and Exchange Commission, or SEC, on February 22, 2012, and other documents filed with the SEC.
The risk factors and other information contained in these documents should be considered in evaluating Questcor's
prospects and future financial performance.


4
335 paid NS scripts
1,291 paid MS scripts
102 paid IS scripts
Financial results
5,590 vials shipped, up 92% YOY
$140.3M in net sales, up 135% YOY
$0.91 GAAP EPS (diluted), up 160% YOY
335 paid NS scripts
1,291 paid MS scripts
102 paid IS scripts
Financial results
5,590 vials shipped, up 92% YOY
$140.3M in net sales, up 135% YOY
$0.91 GAAP EPS (diluted), up 160% YOY
3Q-12 Results


5
Growth in Shipped Vials
0
1,000
2,000
3,000
4,000
5,000
6,000
Q1-10
Q2-10
Q3-10
Q4-10
Q1-11
Q2-11
Q3-11
Q4-11
Q1-12
Q2-12
Q3-12
Shipped Vials
Shipped Vials


6
Paid Rxs
Paid Rxs
NS Scripts-Strong Continued Growth
11
4
8
7
18
45
60
146
238
314
335
Q1 '10
Q2 '10
Q3 '10
Q4 '10
Q1 '11
Q2 '11
Q3 '11
Q4 '11
Q1 '12
Q2 '12
Q3 '12
Notes: Historical trend information is not necessarily indicative of future results.  Chart includes "Related Conditions" - diagnoses that
are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of the chart.


7
Notes: Historical trend information is not necessarily indicative of future results.  Acthar is marketed for the on-label indication of MS
exacerbations
in
adults,
though
the
chart
includes
"Related
Conditions"
-
diagnoses
that
are
either
alternative
descriptions
of
the
condition
or
are closely related to the medical condition which is the focus of the chart. About 5% of the prescriptions in the tables are for related conditions.
Notes: Historical trend information is not necessarily indicative of future results.  Acthar is marketed for the on-label indication of MS
exacerbations
in
adults,
though
the
chart
includes
"Related
Conditions"
-
diagnoses
that
are
either
alternative
descriptions
of
the
condition
or
are closely related to the medical condition which is the focus of the chart. About 5% of the prescriptions in the tables are for related conditions.
MS Scripts-Record of Consistent Growth
Paid Rxs
78
124
141
213
231
304
323
354
508
751
886
945
1,000
1,110
1,291
Q1 '09
Q2 '09
Q3 '09
Q4 '09
Q1 '10
Q2 '10
Q3 '10
Q4 '10
Q1 '11
Q2 '11
Q3 '11
Q4 '11
Q1 '12
Q2 '12
Q3 '12


8
Understanding the biological properties of Acthar
Specific biochemical pathways, cells, and  tissues
Immunomodulation and anti-inflammatory effects
Further research related to on-label indications
Possible new indications to explore
Understanding the biological properties of Acthar
Specific biochemical pathways, cells, and  tissues
Immunomodulation and anti-inflammatory effects
Further research related to on-label indications
Possible new indications to explore
The Emerging Science Behind Acthar
Preclinical and Clinical Studies


9
335 paid NS scripts
1,291 paid MS scripts
102 paid IS scripts
Financial results
5,590 vials shipped, up 92% YOY
$140.3M in net sales, up 135% YOY
$0.91 GAAP EPS (diluted), up 160% YOY
335 paid NS scripts
1,291 paid MS scripts
102 paid IS scripts
Financial results
5,590 vials shipped, up 92% YOY
$140.3M in net sales, up 135% YOY
$0.91 GAAP EPS (diluted), up 160% YOY
3Q-12 Results


10
10
Third Quarter 2012
Conference Call
Third Quarter 2012
Conference Call
NASDAQ:
QCOR